Key result
Patients with neuromuscular diseases such as Duchenne muscular dystrophy and polymyositis can have serum MB-CPK constituting 5% to 30% of total CPK, indicating it is not specific for myocardial injury.
Why the study?
Is serum MB-CPK elevation a specific indicator of myocardial injury?
Is serum MB-CPK elevation a specific indicator of myocardial injury?
Elevation of the MB isoenzyme of creatine phosphokinase (MB-CPK) is not specific to myocardial infarction and can be significantly elevated in patients with neuromuscular diseases.
To the Editor.— We disagree with the conclusion of Roberts and Sobel (Archives136:421-424, 1976) that increase of the MB isoenzyme of creatine phosphokinase (MB-CPK) in the serum is a specific indicator of myocardial injury. They did demonstrate the absence of MB-CPK from normal skeletal muscle, in agreement with others, 1,2 but they did not consider abnormal skeletal muscle, which is known to produce MB-CPK. Substantial amounts of MB (10% to 30% of total CPK) are present in skeletal muscle biopsy specimens of certain patients with active myopathy, including all of those with Duchenne muscular dystrophy, in some patients with chronic denervation, and occasionally in other patients with other neuromuscular disorders (eg, myotonic atrophy). 1,2 In our own study, as in studies by others, 3 patients with various neuromuscular diseases have shown serum MB-CPK constituting significant fractions of total serum CPK activity: especially Duchenne dystrophy and polymyositis (5% to 30%),
No takes yet. Share an insight, caveat, or question.
Bruce T. Adornato (1977) conducted a letter in Neuromuscular diseases. Neuromuscular diseases was evaluated on Serum MB-CPK fraction of total serum CPK activity. Patients with neuromuscular diseases such as Duchenne muscular dystrophy and polymyositis can have serum MB-CPK constituting 5% to 30% of total CPK, indicating it is not specific for myocardial injury.
Synapse has enriched 5 related papers. Consider them for comparative context: